By Design
Solving Immunogenicity at the Scaffold Level
VestraNova has developed a computational antibody platform that reduces predicted immunogenic epitope liabilities at the framework level — before CDR grafting, before payload conjugation, across multiple targets and modalities.
What We're Building
A Platform, Not a Single Asset
VestraNova is building a reusable antibody scaffold platform for oncology. Instead of designing each therapeutic independently, we engineer the underlying antibody framework itself. That foundation can then be applied across multiple targets and programs. The goal is to create a shared structural backbone that supports a growing pipeline of therapies, rather than rebuilding from scratch each time.
Why This Matters
Better-Designed Medicines Start with a Better Foundation
When patients receive antibody-based therapies, their immune systems can sometimes recognize foreign elements in the drug itself. This can reduce effectiveness, cause adverse reactions, and limit how long a patient can stay on treatment. We aim to address this at the molecular level — before it becomes a clinical problem.
The Overlooked Risk
Most therapeutic antibodies are built on frameworks that were never systematically optimized for immune compatibility across diverse patient populations.
Per-Molecule Band-Aids
The industry treats immunogenicity as a per-molecule cost: point-mutate epitopes, PEGylate, or co-administer immunosuppressants. Expensive and target-specific.
A Platform-Level Solution
This is not a per-drug problem. It is a platform-level engineering gap. We designed a single engineered foundation intended to address this across multiple targets.
Patient Impact
What This Means for Patients
Better-engineered antibody foundations are designed to support therapies that patients may be better able to tolerate and remain on over time.
Fewer Hidden Barriers
Addressing immunogenicity risk upstream aims to reduce a category of treatment failure that often goes undetected until late-stage development.
Designed for Tolerability
A deimmunized scaffold is intended to help future therapies be better tolerated, supporting treatment continuity.
Broader Patient Coverage
Assessed across HLA alleles covering more than 85% of the global population, aiming for relevance across diverse patients.
Platform Logic
Built for Platform Leverage
VestraNova's approach starts with scaffold engineering, then extends that architecture across oncology targets. This model is designed to create a common technical foundation across programs and enable more efficient expansion of the pipeline.
Next Milestone
Next Platform Inflection Point: Full Wet-Lab Validation
Our next milestone is full wet-lab validation of scaffold de-immunization — including PBMC-based human immune cell assays, T-cell proliferation testing, and cytokine profiling. This is not a partial read. It is a comprehensive experimental program designed to test the central platform hypothesis directly.
One experiment. Platform-wide implications.
A successful result would not apply to a single therapeutic candidate alone, but to the underlying scaffold used across the entire VestraNova platform.
Our Approach
How We Build Programs
We do not treat each antibody as a standalone design problem. We begin with a shared engineered scaffold and extend it across multiple targets and formats.
- Create consistency across programs
- Support a unified validation strategy
- Enable scalable pipeline development
Pipeline
Pipeline Under Development
VestraNova is applying its scaffold architecture across a growing set of oncology-relevant targets. Programs are currently computationally profiled and prioritized for downstream development based on platform compatibility.
Evidence Standards
Evidence-First Development
Public materials are intentionally conservative. Technical datasets, structural analyses, and program-level evidence are shared selectively in diligence settings and under appropriate confidentiality protections.
Request Additional Information
A detailed overview of the platform, validation plan, and development strategy is available upon request.